NO20081026L - Kinolinderivater som antibakterielle midler - Google Patents

Kinolinderivater som antibakterielle midler

Info

Publication number
NO20081026L
NO20081026L NO20081026A NO20081026A NO20081026L NO 20081026 L NO20081026 L NO 20081026L NO 20081026 A NO20081026 A NO 20081026A NO 20081026 A NO20081026 A NO 20081026A NO 20081026 L NO20081026 L NO 20081026L
Authority
NO
Norway
Prior art keywords
alkyl
het
hydrogen
alkylthio
hydroxy
Prior art date
Application number
NO20081026A
Other languages
English (en)
Other versions
NO341242B1 (no
Inventor
Leo Jacobus Jozef Backx
Lieven Meerpoel
Jerome Emile George Guillemont
David Francis Alain Lancois
Koenraad Jozef Lodewij Andries
Anil Koul
Elisabeth Therese Jea Pasquier
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35744723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081026(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20081026L publication Critical patent/NO20081026L/no
Publication of NO341242B1 publication Critical patent/NO341242B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Anvendelse av en forbindelse for fremstilling av et medikament for behandling av en bakteriell infeksjon forutsatt at den bakterielle infeksjon er noe annet enn en mykobakteriell infeksjon, idet nevnte forbindelse er en forbindelse med formel (I) (I) et farmasøytisk akseptabelt syre- eller baseaddisjonssalt, et kvaternært amin, en stereokjemisk isomer form, en tautomer form eller en N-oksidform derav, hvori R1 er hydrogen, halogen, halogenalkyl, cyano, hydroksy, Ar, Het, alkyl, alkyloksy, alkyltio, alkyloksyalkyl, alkyltioalkyl, Ar-alkyl eller di(Ar)alkyl; p er 1 til 3; s er 0 til 4; R2 er hydrogen; halogen; alkyl; hydroksy; merkapto; valgfritt substituert alkyloksy; alkyloksyalkyloksy; alkyltio; mono eller di(alkyl)amino, hvori alkyl kan valgfritt være substituert; Ar; Het eller et radikal med formel ; R3 er alkyl, Ar, Ar-alkyl, Het eller Het-alkyl; q er 0 til 4; R4 og R5 hver uavhengig er hydrogen, alkyl eller benzyl eller R4 og R5 kan være tatt sammen iberegnet N-atomet som de er bundet til; R6 er hydrogen, halogen, halogenalkyl, hydroksy, Ar, alkyl, alkyloksy, alkyltio, alkyloksyalkyl, alkyltioalkyl, Ar-alkyl eller di(Ar)alkyl, eller to nærliggende R6-radikaler kan være tatt sammen og danner sammen med fenylringen som de er bundet til, et naftyl; r er 1 til 5; R7 er hydrogen, alkyl, Ar eller Het; R8 er hydrogen, alkyl, hydroksyl, aminokarbonyl, mono-eller di(alkyl)aminokarbonyl, Ar, Het, alkyl substituert med ett eller to Het, alkyl substituert med ett eller to Ar, Het-C(=O)- eller Ar-C(=O)-; forutsatt at når det R3-bærende radikal er plassert i stilling 3 i kinolingruppen; R7 er plassert i stilling 4, og R2 er plassert i stilling 2 og representerer hydrogen, hydroksy, merkapto, alkyloksy, alkyloksyalkyloksy, alkyltio, mono eller di(alkyl)amino eller et radikal med formel , da er s 1 til 4.
NO20081026A 2005-08-03 2008-02-27 Kinolinderivater som antibakterielle midler NO341242B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107164 2005-08-03
PCT/EP2006/064858 WO2007014941A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents

Publications (2)

Publication Number Publication Date
NO20081026L true NO20081026L (no) 2008-02-27
NO341242B1 NO341242B1 (no) 2017-09-25

Family

ID=35744723

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081026A NO341242B1 (no) 2005-08-03 2008-02-27 Kinolinderivater som antibakterielle midler

Country Status (31)

Country Link
US (1) US8802671B2 (no)
EP (1) EP1912648B1 (no)
JP (1) JP5302680B2 (no)
KR (1) KR101413997B1 (no)
CN (2) CN101277696B8 (no)
AP (1) AP2654A (no)
AR (1) AR054890A1 (no)
AU (1) AU2006274880B2 (no)
BR (1) BRPI0614493B8 (no)
CA (1) CA2615903C (no)
CY (1) CY1114318T1 (no)
DK (1) DK1912648T3 (no)
EA (1) EA014833B1 (no)
ES (1) ES2414956T3 (no)
HK (1) HK1124234A1 (no)
HR (1) HRP20130540T1 (no)
IL (1) IL189142A0 (no)
JO (1) JO2855B1 (no)
ME (1) ME01616B (no)
MX (1) MX2008001603A (no)
MY (1) MY159560A (no)
NO (1) NO341242B1 (no)
NZ (1) NZ565947A (no)
PL (1) PL1912648T3 (no)
PT (1) PT1912648E (no)
RS (1) RS52808B (no)
SI (1) SI1912648T1 (no)
TW (1) TWI422374B (no)
UA (1) UA95915C2 (no)
WO (1) WO2007014941A2 (no)
ZA (1) ZA200801110B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004186452A (ja) 2002-12-04 2004-07-02 Renesas Technology Corp 不揮発性半導体記憶装置およびその製造方法
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
MX355050B (es) 2012-04-27 2018-04-02 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos.
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
AU2013331505A1 (en) 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ.ベー. Rorγtのアルキル結合キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CN109111396B (zh) * 2018-08-28 2021-09-03 广东工业大学 一种喹啉芳香乙烯衍生物及其制备方法和应用
CN109111397B (zh) * 2018-08-28 2021-12-10 广东工业大学 一种喹啉芳香乙烯类衍生物及其制备方法和应用
CN112079825B (zh) * 2020-10-09 2021-12-21 中央民族大学 含1,3-二氧戊环二聚双噻吩结构的化合物及其制备方法和应用
CN112110907B (zh) * 2020-10-09 2021-12-21 中央民族大学 一种含1,4-二氧六环二聚双噻吩结构的化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB807750A (en) 1956-06-15 1959-01-21 Rhone Poulenc Sa Improvements in or relating to piperazine derivatives
GB9317491D0 (en) * 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
JP4484703B2 (ja) * 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
PL360102A3 (en) 2003-05-13 2004-11-15 "ENERGOMAR-NORD" Sp.z o.o. Method for manufacturing highly reactive calcium sorbing agents and facility designed for manufacturing highly reactive calcium sorbing agents
EA011277B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
ATE392423T1 (de) 2004-01-23 2008-05-15 Janssen Pharmaceutica Nv Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien
WO2005075428A1 (en) * 2004-01-29 2005-08-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
EE05697B1 (et) 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
US20070018948A1 (en) 2005-07-22 2007-01-25 Elaine Chen Apparatus for stabilizing an electronic device during data input and device control

Also Published As

Publication number Publication date
ES2414956T3 (es) 2013-07-23
WO2007014941A2 (en) 2007-02-08
MY159560A (en) 2017-01-13
EA200800508A1 (ru) 2008-06-30
PL1912648T3 (pl) 2013-08-30
EP1912648A2 (en) 2008-04-23
AP2654A (en) 2013-04-25
KR20080035666A (ko) 2008-04-23
US8802671B2 (en) 2014-08-12
DK1912648T3 (da) 2013-06-24
SI1912648T1 (sl) 2013-07-31
KR101413997B1 (ko) 2014-07-01
BRPI0614493B8 (pt) 2021-05-25
AU2006274880A1 (en) 2007-02-08
CA2615903C (en) 2016-08-30
EA014833B1 (ru) 2011-02-28
IL189142A0 (en) 2008-08-07
HK1124234A1 (zh) 2009-07-10
CN101277696B (zh) 2015-09-02
AU2006274880B2 (en) 2012-12-13
US20080207687A1 (en) 2008-08-28
WO2007014941A8 (en) 2007-05-31
JP5302680B2 (ja) 2013-10-02
TWI422374B (zh) 2014-01-11
RS52808B (en) 2013-10-31
JO2855B1 (en) 2015-03-15
UA95915C2 (ru) 2011-09-26
CA2615903A1 (en) 2007-02-08
NZ565947A (en) 2011-05-27
PT1912648E (pt) 2013-06-27
HRP20130540T1 (en) 2013-07-31
CN101277696B8 (zh) 2016-07-06
CN101277696A (zh) 2008-10-01
MX2008001603A (es) 2008-02-19
AR054890A1 (es) 2007-07-25
JP2009503025A (ja) 2009-01-29
WO2007014941A3 (en) 2007-03-29
CY1114318T1 (el) 2016-08-31
EP1912648B1 (en) 2013-04-10
TW200744595A (en) 2007-12-16
NO341242B1 (no) 2017-09-25
ME01616B (me) 2014-09-20
ZA200801110B (en) 2011-10-26
BRPI0614493B1 (pt) 2019-11-12
BRPI0614493A2 (pt) 2011-03-29

Similar Documents

Publication Publication Date Title
NO20081026L (no) Kinolinderivater som antibakterielle midler
NO20080955L (no) Kinolinderivater som antibakterielle midler
MY177250A (en) Novel nicotinamide derivative or salt thereof
NO20073823L (no) Kinolinderivater for behandlingen av latent tuberkulose
NO20080064L (no) Kinolinderivater som antibakterielle midler
TR200103497T2 (tr) Beta2-adrenoseptör agonistler.
NO20080499L (no) Kinolinderivater som antibakterielle midler
NO20081068L (no) Kinolinderivater som antibakterielle midler
NO20080501L (no) Kinolinderivater som antibakterielle midler
NO20080481L (no) Kinolinderivater som antibakterielle midler
EA200500802A1 (ru) Лечение латентного туберкулёза
TH87171B (th) อนุพันธ์ควิโนลีนเป็นสารต้านแบคทีเรีย

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees